Genprex, Inc. (NASDAQ:GNPX) Short Interest Update

Genprex, Inc. (NASDAQ:GNPX) was the recipient of a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 634,600 shares, a growth of 46.5% from the November 30th total of 433,100 shares. Based on an average daily volume of 9,290,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 7.7% of the company’s stock are short sold.

Genprex Price Performance

GNPX stock traded down $0.01 during trading on Monday, reaching $0.86. 198,370 shares of the company traded hands, compared to its average volume of 2,561,180. The business has a 50 day simple moving average of $1.43 and a 200 day simple moving average of $1.24. Genprex has a 12 month low of $0.28 and a 12 month high of $14.40.

Institutional Trading of Genprex

A hedge fund recently raised its stake in Genprex stock. Armistice Capital LLC raised its stake in Genprex, Inc. (NASDAQ:GNPX) by 122.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 218,000 shares of the company’s stock after acquiring an additional 120,132 shares during the quarter. Armistice Capital LLC owned approximately 10.39% of Genprex worth $411,000 at the end of the most recent reporting period. 14.05% of the stock is currently owned by institutional investors and hedge funds.

Genprex Company Profile

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.